Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. Issue 29 (10th October 2022)

• Record Type: Journal Article
• Authors: Deek, Matthew P.; Van der Eecken, Kim; Sutera, Philip; Deek, Rebecca A.; Fonteyne, Valérie; Mendes, Adrianna A.; Decaestecker, Karel; Kiess, Ana Ponce; Lumen, Nicolaas; Phillips, Ryan; De Bruycker, Aurélie; Mishra, Mark; Rana, Zaker; Molitoris, Jason; Lambert, Bieke; Delrue, Louke; Wang, Hailun; Lowe, Kathryn; Verbeke, Sofie; Van Dorpe, Jo; Bultijnck, Renée; Villeirs, Geert; De Man, Kathia; Ameye, Filip; Song, Daniel Y.; DeWeese, Theodore; Paller, Channing J.; Feng, Felix Y.; Wyatt, Alexander; Pienta, Kenneth J.; Diehn, Maximillian; Bentzen, Soren M.; Joniau, Steven; Vanhaverbeke, Friedl; De Meerleer, Gert; Antonarakis, Emmanuel S.; Lotan, Tamara L.; Berlin, Alejandro; Siva, Shankar; Ost, Piet; Tran, Phuoc T.;
• Is Part Of: Journal of clinical oncology. Volume 40:Issue 29(2022)
• Page Start: 3377
• Page End: 3382
• Publication Date: 2022-10-10
• Subjects: Oncology -- Periodicals; Cancer -- Periodicals; Oncology; Medical Oncology; Cancérologie -- Périodiques; Cancer -- Périodiques; Cancérologie; Cancer; Oncology; Oncologia; Càncer; Periodicals; 616.994
• DOI: 10.1200/JCO.22.00644
• Languages: English
• ISSNs: 0732-183X

Abstract

Abstract : Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1 / 2, Rb1, or TP53 . The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.